• Used alone and in combination with other treatment modalities (antineoplastics, surgery, or radiation therapy) in treatment of:
  • Hodgkin’s disease,
  • Leukemias,
  • Neuroblastoma,
  • Malignant lymphomas,
  • Rhabdomyosarcoma,
  • Wilms’ tumor,
  • Other tumors.

Contraindicated in:

• Hypersensitivity
• OB: Pregnancy
• Lactation: Lactation.

Use Cautiously in:

• Infection
• ↓bone marrow reserve
• Hepatic impairment (50% dose ↓ recommended if serum bilirubin >3 mg/dL)
• Rep: Women of reproductive potential

Derm: alopecia.

EENT: cortical blindness, diplopia.

Endo: syndrome of inappropriate antidiuretic hormone (SIADH).

GI: nausea, vomiting, abdominal cramps, anorexia, constipation, ileus, stomatitis.

GU: gonadal suppression, nocturia, oliguria, urinary retention.

Hemat: anemia, leukopenia, thrombocytopenia (mild and brief).

Local: phlebitis at IV site, tissue necrosis (from extravasation).

Metab: hyperuricemia.

Neuro: ascending peripheral neuropathy, agitation, insomnia, mental depression, mental status changes.

Resp: bronchospasm.

Drug-Drug:

• Bronchospasm may occur in patients who have been previously treated with mitomycin.
• l-asparaginase may ↓ hepatic metabolism of vincristine (give vincristine 12–24 hr prior to asparaginase).
• May ↓ antibody response to live-virus vaccines and ↑ risk of adverse reactions.

(Generic available)

• Solution for injection: 1 mg/mL;

• IV (Adults): 10–30 mcg/kg (0.4–1.4 mg/m²); may repeat weekly (not to exceed 2 mg/dose).
• IV (Children >10 kg): 1.5–2 mg/m² single dose; may repeat weekly.
• IV (Children <10 kg): 50 mcg/kg single dose; may repeat weekly.

Vincasar PFS

• Binds to proteins of mitotic spindle, causing metaphase arrest.
• Cell replication is stopped as a result (cell cycle–specific for M phase).
• Has little or no effect on bone marrow.

• Death of rapidly replicating cells, particularly malignant ones.

Therapeutic Classification: antineoplastics

Pharmacologic Classification: vinca alkaloids

Absorption: IV administration results in complete bioavailability.

Distribution: Rapidly and widely distributed; extensively bound to tissues.

Metabolism/Excretion: Metabolized by the liver and eliminated in the feces via biliary excretion.

Half-life: 10.5–37.5 hr.

(effects on blood counts†)

†Usually mild.

• Instruct patient to notify health care professional immediately if redness, swelling, or pain at injection site occurs.
• Instruct patient to report symptoms of neurotoxicity (paresthesia, pain, difficulty walking, persistent constipation). Inform patient that increased fluid intake, dietary fiber, and exercise may minimize constipation. Stool softeners or laxatives may be used. Patient should inform health care professional if severe constipation or abdominal discomfort occurs, as this may be a sign of neuropathy.
• Advise patient to notify health care professional if fever; chills; sore throat; signs of infection; bleeding gums; bruising; petechiae; blood in urine, stool, or emesis; or mouth sores occur. Caution patient to avoid crowds and persons with known infections.
• Discuss with patient the possibility of hair loss. Explore coping strategies.
• Instruct patient not to receive any vaccinations without advice of health care professional.
• Rep: May cause fetal harm. Advise females of reproductive potential to notify health care professional if pregnancy is planned or suspected and to avoid breastfeeding during therapy. Contraception should be used during and for at least 2 mo after therapy is concluded.
• Emphasize need for periodic lab tests to monitor for side effects.

vin-KRISS-teen

NDC Code^*

• 20536- Talon Therapeutics, Inc.
  • 20536-322- Marqibo
    • 20536-322-01- 1 KIT in 1 CARTON (20536-322-01) * 1 mL in 1 VIAL, GLASS (20536-324-01) * 25 mL in 1 VIAL, GLASS (20536-325-01) * 5 mL in 1 VIAL, GLASS (20536-323-01)

• 61703- Hospira, Inc.
  • 61703-309- VinCRIStine Sulfate
    • 61703-309-06- 1 VIAL, SINGLE-USE in 1 CARTON (61703-309-06) > 1 mL in 1 VIAL, SINGLE-USE

• 61703- Hospira, Inc.
  • 61703-309- VinCRIStine Sulfate
    • 61703-309-16- 1 VIAL, SINGLE-USE in 1 CARTON (61703-309-16) > 2 mL in 1 VIAL, SINGLE-USE

• 61703- Hospira, Inc.
  • 61703-309- VinCRIStine Sulfate
    • 61703-309-25- 1 VIAL, SINGLE-DOSE in 1 CARTON (61703-309-25) > 2 mL in 1 VIAL, SINGLE-DOSE

• 61703- Hospira, Inc.
  • 61703-309- VinCRIStine Sulfate
    • 61703-309-26- 1 VIAL, SINGLE-DOSE in 1 CARTON (61703-309-26) > 1 mL in 1 VIAL, SINGLE-DOSE

• 72893- Acrotech Biopharma LLC
  • 72893-008- Marqibo
    • 72893-008-03- 1 KIT in 1 CARTON (72893-008-03) * 1 mL in 1 VIAL, GLASS (72893-011-05) * 25 mL in 1 VIAL, GLASS (72893-010-05) * 5 mL in 1 VIAL, GLASS (72893-012-05)